CPX-351 (Vyxeos) Can Cause Severe Rash in Acute Myeloid Leukemia-A Case Report

Overview

Journal Clin Case Rep

Date 2021 May 3

PMID 33936618

Citations 3

Authors

Ruth M Urbantat

Valentin Popper

Elisabeth Menschel

Michael Pfeilstocker

Ernst Forjan

Alexander Nader

Catherine R Sieghart

Felix Keil

Elisabeth Koller

Affiliations

Soon will be listed here.

Abstract

CPX-351, a promising new agent for patients with treatment-related and secondary acute myeloid leukemia can lead to a severe whole-body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.

Citing Articles

Dermatologic complications in transplantation and cellular therapy for acute leukemia.

Babakoohi S, Gu S, Ehsan H, Markova A Best Pract Res Clin Haematol. 2023; 36(2):101464.

PMID: 37353285 PMC: 10291442. DOI: 10.1016/j.beha.2023.101464.

CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML.

Molica M, Perrone S, Mazzone C, Cesini L, Canichella M, de Fabritiis P Cancers (Basel). 2022; 14(12).

PMID: 35740508 PMC: 9221356. DOI: 10.3390/cancers14122843.

CPX-351 (Vyxeos) can cause severe rash in acute myeloid leukemia-A case report.

Urbantat R, Popper V, Menschel E, Pfeilstocker M, Forjan E, Nader A Clin Case Rep. 2021; 9(4):1933-1936.

PMID: 33936618 PMC: 8077323. DOI: 10.1002/ccr3.3909.

References

Fitzpatrick J . The cutaneous histopathology of chemotherapeutic reactions. J Cutan Pathol. 1993; 20(1):1-14. DOI: 10.1111/j.1600-0560.1993.tb01242.x. View

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976; 33(4):451-8. DOI: 10.1111/j.1365-2141.1976.tb03563.x. View

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

Giles A, Foushee J, Lantz E, Gumina G . Sulfonamide Allergies. Pharmacy (Basel). 2019; 7(3). PMC: 6789825. DOI: 10.3390/pharmacy7030132. View

Krauss A, Gao X, Li L, Manning M, Patel P, Fu W . FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia. Clin Cancer Res. 2018; 25(9):2685-2690. DOI: 10.1158/1078-0432.CCR-18-2990. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

Urbantat R, Popper V, Menschel E, Pfeilstocker M, Forjan E, Nader A . CPX-351 (Vyxeos) can cause severe rash in acute myeloid leukemia-A case report. Clin Case Rep. 2021; 9(4):1933-1936. PMC: 8077323. DOI: 10.1002/ccr3.3909. View

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

Ammannagari N, Kaewpoowat Q, Ratanapo S, Patel A . Florid skin rash in acute myeloid leukaemia. BMJ Case Rep. 2013; 2013. PMC: 3618765. DOI: 10.1136/bcr-2012-008159. View

10.

Kim R, Peterson G, Kulp B, Zanotti K, Markman M . Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. Gynecol Oncol. 2005; 97(2):374-8. DOI: 10.1016/j.ygyno.2004.12.057. View

11.

Palmieri R, Paterno G, De Bellis E, Mercante L, Buzzatti E, Esposito F . Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of Fitness. Cancers (Basel). 2020; 12(1). PMC: 7016986. DOI: 10.3390/cancers12010120. View

12.

Cetkovska P, Pizinger K, Cetkovsky P . High-dose cytosine arabinoside-induced cutaneous reactions. J Eur Acad Dermatol Venereol. 2002; 16(5):481-5. DOI: 10.1046/j.1468-3083.2002.00395.x. View

13.

Von Moos R, Thuerlimann B, Aapro M, Rayson D, Harrold K, Sehouli J . Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer. 2008; 44(6):781-90. DOI: 10.1016/j.ejca.2008.01.028. View

14.

Jick H . Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis. 1982; 4(2):426-8. DOI: 10.1093/clinids/4.2.426. View

15.

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

16.

Macy E, Poon K-Y T . Self-reported antibiotic allergy incidence and prevalence: age and sex effects. Am J Med. 2009; 122(8):778.e1-7. DOI: 10.1016/j.amjmed.2009.01.034. View

17.

Lancet J, Uy G, Cortes J, Newell L, Lin T, Ritchie E . CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol. 2018; 36(26):2684-2692. PMC: 6127025. DOI: 10.1200/JCO.2017.77.6112. View

18.

Grunwald M, McDonnell M, Induru R, Gerber J . Cutaneous manifestations in leukemia patients. Semin Oncol. 2016; 43(3):359-65. DOI: 10.1053/j.seminoncol.2016.02.020. View

19.

Rosenbeck L, Kiel P . Images in clinical medicine. Palmar-plantar rash with cytarabine therapy. N Engl J Med. 2011; 364(3):e5. DOI: 10.1056/NEJMicm1006530. View

20.

Sorror M, Maris M, Storb R, Baron F, Sandmaier B, Maloney D . Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106(8):2912-9. PMC: 1895304. DOI: 10.1182/blood-2005-05-2004. View